Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Flutamide

FDA-approved product (capsule, oral), marketed as Eulexin, Flutamide.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Flutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Carcinoma
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-androgens
FDA pharmacologic class
Androgen Receptor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli13.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Flutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Flutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

    NCT00030654 · start 2002-10

    Registered record
    Registry ID
    NCT00030654
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; docetaxel; doxorubicin hydrochloride; estramustine phosphate sodium; flutamide; ketoconazole; paclitaxel; releasing hormone agonist therapy; vinblastine sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-10
    Completion
    2005-02-04
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; docetaxel; doxorubicin hydrochloride; estramustine phosphate sodium +5 more
    PhasePhase 3
    Registry statusCompleted

  • S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

    NCT00028769 · start 2001-12

    Registered record
    Registry ID
    NCT00028769
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; estramustine; etoposide; flutamide; goserelin; leuprolide; nilutamide; paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-12
    Completion
    2011-07
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; estramustine; etoposide; flutamide +4 more
    PhasePhase 2
    Registry statusCompleted

  • SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

    NCT00026377 · start 2001-11

    Registered record
    Registry ID
    NCT00026377
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; flutamide; goserelin acetate; leuprolide acetate; SU5416; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-11
    Completion
    2003-04
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; flutamide; goserelin acetate; leuprolide acetate +2 more
    PhasePhase 1
    Registry statusCompleted

  • Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer

    NCT00023829 · start 2001-08

    Registered record
    Registry ID
    NCT00023829
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; flutamide; releasing hormone agonist therapy; adjuvant therapy; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-08
    Completion
    2004-06
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; flutamide; releasing hormone agonist therapy; adjuvant therapy +1 more
    PhasePhase 3
    Registry statusCompleted

  • Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer

    NCT00006359 · start 2000-09

    Registered record
    Registry ID
    NCT00006359
    Conditions
    Prostate Cancer
    Interventions
    LHRH agonist; antiandrogen; radiation therapy; Brachytherapy boost
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-09
    Completion
    2012-03
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionLHRH agonist; antiandrogen; radiation therapy; Brachytherapy boost
    PhasePhase 2
    Registry statusCompleted

  • Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate

    NCT00006214 · start 2000-08

    Registered record
    Registry ID
    NCT00006214
    Conditions
    Prostate Cancer
    Interventions
    flutamide; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-08
    Completion
    2006-07
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionflutamide; placebo
    PhasePhase 2
    Registry statusCompleted

  • Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer

    NCT02911350 · start 2000-05

    Registered record
    Registry ID
    NCT02911350
    Conditions
    Prostate Cancer
    Interventions
    Hormone Suppressors; Paclitaxel; Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2000-05
    Completion
    2016-12
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionHormone Suppressors; Paclitaxel; Radiation Therapy
    PhasePhase 1
    Registry statusCompleted

  • Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer

    NCT01122121 · start 2000-03

    Registered record
    Registry ID
    NCT01122121
    Conditions
    Prostatic Neoplasms, Locally Advanced
    Interventions
    Leuprorelin SR; Radiotherapy; Flutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-03
    Completion
    2009-06
    Enrolment
    273

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms, Locally Advanced
    InterventionLeuprorelin SR; Radiotherapy; Flutamide
    PhasePhase 3
    Registry statusCompleted

  • Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

    NCT00003653 · start 1999-01-05

    Registered record
    Registry ID
    NCT00003653
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; buserelin; cyproterone acetate; flutamide; goserelin; leuprolide acetate; nilutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-01-05
    Completion
    2013-01-10
    Enrolment
    1,386

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; buserelin; cyproterone acetate; flutamide +3 more
    PhasePhase 3
    Registry statusCompleted

  • Hormone Therapy in Treating Patients With Prostate Cancer

    NCT00003323 · start 1998-05

    Registered record
    Registry ID
    NCT00003323
    Conditions
    Prostate Cancer; Sexual Dysfunction and Infertility
    Interventions
    finasteride; flutamide; quality-of-life assessment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1998-05
    Completion
    2010-03
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Sexual Dysfunction and Infertility
    Interventionfinasteride; flutamide; quality-of-life assessment
    PhasePhase 2
    Registry statusCompleted

  • Hormone Therapy in Treating Patients With Advanced Prostate Cancer

    NCT00003026 · start 1997-04

    Registered record
    Registry ID
    NCT00003026
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; flutamide; triptorelin; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-04
    Completion
    Not recorded
    Enrolment
    966

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; flutamide; triptorelin; radiation therapy
    PhasePhase 3
    Registry statusCompleted

  • Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer

    NCT00223665 · start 1997-01-08

    Registered record
    Registry ID
    NCT00223665
    Conditions
    Prostate Cancer
    Interventions
    Flutamide; Leuprolide Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-01-08
    Completion
    2012-09-06
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionFlutamide; Leuprolide Acetate
    PhasePhase 2
    Registry statusCompleted

  • Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

    NCT00002881 · start 1996-10

    Registered record
    Registry ID
    NCT00002881
    Conditions
    Prostate Cancer
    Interventions
    flutamide; goserelin acetate; leuprolide acetate; suramin; therapeutic hydrocortisone; orchiectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1996-10
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionflutamide; goserelin acetate; leuprolide acetate; suramin +2 more
    PhasePhase 3
    Registry statusCompleted

  • Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

    NCT00002855 · start 1996-08

    Registered record
    Registry ID
    NCT00002855
    Conditions
    Prostate Cancer
    Interventions
    Bicalutamide; Doxorubicin hydrochloride; Estramustine Phosphate Sodium; Flutamide; Ketoconazole; Nilutamide; Therapeutic Hydrocortisone; Vinblastine; Conventional Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1996-08
    Completion
    2005-06
    Enrolment
    306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionBicalutamide; Doxorubicin hydrochloride; Estramustine Phosphate Sodium; Flutamide +5 more
    PhasePhase 3
    Registry statusCompleted

  • Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer

    NCT00116220 · start 1995-09

    Registered record
    Registry ID
    NCT00116220
    Conditions
    Prostate Cancer
    Interventions
    Flutamide (Eulexin) and Lupron or Zoladex; External Beam Radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-09
    Completion
    2015-02
    Enrolment
    206

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionFlutamide (Eulexin) and Lupron or Zoladex; External Beam Radiotherapy
    PhasePhase 3
    Registry statusCompleted